Frailty Screening Initiative Cuts Mortality After Surgery

Share this content:
Frailty Screening Initiative Cuts Mortality After Surgery
Frailty Screening Initiative Cuts Mortality After Surgery

THURSDAY, Dec. 1, 2016 (HealthDay News) -- For patients undergoing elective surgery, implementation of the Frailty Screening Initiative (FSI) is associated with a reduction in mortality, according to a study published online Nov. 30 in JAMA Surgery.

Daniel E. Hall, M.D., from the Veterans Affairs Pittsburgh Healthcare System, and colleagues examined the effect of the FSI on mortality and complications by comparing surgical outcomes for patients treated before and after FSI implementation. Data were assessed for all 9,153 patients from a Veterans Affairs medical center who presented for major, elective, noncardiac surgery from Oct. 1, 2007, to July 1, 2014. Assessment of preoperative frailty began in July 2011.

The researchers found that after implementation of FSI, 30-day mortality decreased from 1.6 to 0.7 percent (P < 0.001). The greatest improvement was seen among frail patients (12.2 to 3.8 percent; P < 0.001), although mortality rates also declined among robust patients (1.2 to 0.3 percent; P < 0.001). Among frail patients, the magnitude of improvement increased at 180 and 365 days (23.9 to 7.7 percent and 34.5 to 11.7 percent, respectively; both P < 0.001). Controlling for age, frailty, and predicted mortality, survival improved after FSI implementation (adjusted odds ratio for 180-day survival, 2.87).

"Implementation of the FSI was associated with reduced mortality, suggesting the feasibility of widespread screening of patients preoperatively to identify frailty and the efficacy of system-level initiatives aimed at improving their surgical outcomes," the authors write.

One author reported holding intellectual property on frailty through FutureAssure.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »